Evidence map›Paper›PMID 42682804›Full record

ArticleFrontiers in bioinformatics2026

A recurrently perturbed 12-gene program marks drug-tolerant persister states across cancer types.

Itika Arora, Ahmed Mohammed Adam, Abdullah O Aljaylani, Jumana Z Alzuhayri, Ehab M M Ali, Faisal A Alzahrani, Mohammad Imran Khan, Ahmed Yaqinuddin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Itika Arora *College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Ahmed Mohammed Adam *Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Abdullah O AljaylaniResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Jumana Z AlzuhayriResearch Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Ehab M M AliDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Faisal A AlzahraniDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Mohammad Imran KhanCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Ahmed YaqinuddinCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-tolerant persister (DTP) cells survive therapeutic stress through reversible, non-genetic adaptations, driving treatment failure across cancers. Whether a recurrently perturbed program defines the DTP state across cancer types remains poorly characterized. We performed integrated transcriptomic analysis across five GEO RNA-seq datasets representing breast, lung, pancreatic, colorectal, and melanoma DTP models. A stringent 12-gene signature, PanDTP-12, was established from genes meeting differential expression criteria (FDR <0.001, |log

Indexed as

cancer drug resistanceclinical utilitydrug-tolerant persister cellsferroptosisgene expression profiling

Identifiers

PMID42682804
PMCPMC13530430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.